International Journal of Life Sciences, Biotechnology and Pharma Research Vol. 14, No. 2, February 2025 Online ISSN: 2250-3137
Print ISSN: 2977-0122

DOI: 10.69605/ijlbpr_14.2.2025.58

ORIGINAL RESEARCH

Tumor infiltrating Lymphocytes and its association with prognosis in Colorectal Carcinoma

[1]Dr. Anilkumar Sirasagi, [2]Dr. Vara Prasad BM, [3]Dr. Ayesha Iram

[1]Professor and HOD, [2]Associate Professor, [3]Postgraduate, Department of Pathology, ESIC Medical College and PGIMSR, Rajajinagar,Bangalore, Karnataka, India.

Corresponding Author:
Dr. Ayesha Iram, Postgraduate, Department of Pathology
ESIC Medical College and PGIMSR, Rajajinagar, Bangalore, Karnataka, India
Email: ayeshairam199527@gmail.com

Received: 22December, 2024 Accepted:27January, 2025

Abstract:
Introduction: Histopathological examination of colorectal cancer (CRC) often interprets tumor-infiltrating lymphocytes (TILs) as the host defence mechanism preventing tumour progression. Independent of conventional prognostic markers, tumour infiltration by T cells provides a wealth of information on CRC prognosis. Immunotherapy is becoming a major tool in the fight against colorectal cancer. Melanoma, lung cancer, and colorectal cancer are only a few of the solid tumours for which TILs have shown predictive and prognostic utility.
MaterialsandMethods: We went back over the records at ESIC MC and PGIMSR,Rajajinagar, Bangalore, Department of Pathology. This research includes all instances of colonectomy performed after a diagnosis of colorectal cancer. The research did not include patients who had already had neoadjuvant chemotherapy or radiation. According to the protocol, tumour sections stained with H and E were located in the archives, and lymphocytes infiltrating the tumour were counted.
Results
The research covered the period from January 2022 to August 2024 and comprised 30 instances of colorectal carcinomas identified from resection tissues collected by the Department of Pathology. A total of 16 girls and 14 men (a ratio of 0.875:1) participated in the research. There was a wide age range, from 35 to 74 years old, with 54 being the average. The colon had more tumors than the rectum. The score for TILs was determined.
Conclusions
Tumours in their advanced stages with low-grade TIL tend to have a worse prognosis. Therefore, TIL must be included in pathology reports in order to stratify patients based on risk.
Key words: Colorectal Carcinoma, Tumor, Lymphocytes, Loss, Tubo-Tympanoplasty, Grafts, Graft Placement Time.

Introduction

One of the most prevalent forms of cancer in the digestive system, colorectal cancer affects people all over the globe[1].One of the most prevalent malignant tumours of the digestive tract is colorectal cancer (CRC)[2]. Around 10% of all cancer cases and 9.4% of all cancer deaths occur in colorectal cancer, with 1.9 million newly diagnosed patients and 935,000 fatalities directly attributable to the disease in 2020.Worldwide, it ranks as the second most lethal form of cancer. Among newly diagnosed malignant tumours, the estimated incidence of colorectal cancer is 10.2% and the fatality rate is 9.2%[1]. Histopathological examination of colorectal cancer (CRC) often interprets tumor-infiltrating lymphocytes (TILs) as the host defence mechanism preventing tumour progression[3].

One of the most useful prognostic factors for colorectal cancer prognosis is tumour infiltration by T cells, which stands apart from conventional prognostic markers. With a one-third mortality rate after curative resection surgery within five years, it is crucial to provide risk-specific treatment plans to enhance prognosis[4]. The use of immunotherapy as a treatment for colorectal cancer has recently grown in prominence[5–6]. TILs have shown predictive and prognostic significance in several solid malignancies, such as melanoma, lung cancer, and colorectal cancer (CRC)[7].

The role of cytotoxic T lymphocytes (CD8+ T cells) as an effector mechanism of anti-tumor immunity is well acknowledged[8]. The tumour cells must expose antigens in conjunction with human leukocyte antigen (HLA) class I proteins for CD8+ T lymphocytes to

DOI: 10.69605/ijlbpr_14.2.2025.58

recognise them. Cytotoxic T cells undergo clonal expansion and differentiation when they come into contact with a tumour cell antigen/HLA I complex that their T cell receptor is specific for Multiple kinds of granzymes and a plethora of modified lysosomes containing perforin are produced during killer cell development[9,10] By releasing these lytic components in the event of direct cell-cell contact, activated cytotoxic T lymphocytes may facilitate the particular killing of tumour cells. The release of perforin and enzymatic proteases like granzyme B triggers cell death by membrane rupture and apoptotic pathway activation, respectively[8,11]. Antigen presentation cells (such as dendritic cells) contain HLA class II proteins, which are essential for antitumor immunity. CD4+ T cells are the only cells that react to antigens given by these cells. There are two subtypes of CD4+ T cells, T helper-1 and T helper-2, that are determined by the cytokine profile that is produced. Crucially, cytotoxic T lymphocyte proliferation is dependent on the interleukin-2 generated by T helper-1 effector cells, which in turn requires T helper-1 cells. On the other hand, tumour cells have time to evade the immune system since it takes time to induce cytotoxic T lymphocyte responses. Since innate immune system natural killer cells may lyse tumour targets that are susceptible to natural killers before they become antigen sensitive or undergo clonal proliferation, it follows that these cells may potentially play a significant role. Inhibitory receptors on natural killer cells deactivate HLA complexes upon recognition. Another interesting feature is that natural killer cells have the ability to trigger cell death in cancer cells. Dendritic cells and macrophages then engulf these cells and prepare them for presentation to T cells. On top of that, natural killer cells have the interleukin-2 receptor expressed on a cell-autonomous basis, so they may react to this molecule by increasing their cytotoxic activity[9].

Multiple research have looked at the possibility that immune-cell infiltrates in different types of tumours, such as colorectal cancer, affect patients' prognoses, but their findings have been equivocal[12,13,14]. Clinical outcomes were better for patients with stage III colorectal tumours that included a high concentration of intratumoral lymphocytes, according to several research groups[15,16]. An increased 5-year survival rate has been achieved by the optimisation of screening and the implementation of different therapies, all made possible by a better knowledge of the pathophysiology in colorectal cancer[2].

Materials and methods

We went back over the records at ESIC MC and PGIMSR,Rajajinagar, Bangalore, Department of Pathology. This research includes all instances of colonectomy performed after a diagnosis of colorectal cancer. The research did not include patients who had already had neoadjuvantchemotherapy or radiation. According to the protocol, tumour sections stained with H and E were located in the archives, and lymphocytes infiltrating the tumour were counted.

The Institutional Ethical Committee gave its stamp of approval to this retrospective investigation.

On the invasive front of the main tumour mass were the TIL studies conducted. Using a four-degree scale, the overall inflammatory reaction was evaluated. Without a response, the score would be 0, weak, moderate, and severe. With a score of 0, there was no rise in inflammatory cells; with a score of 1, there was a little and patchy increase of inflammatory cells along the invasive boundary, but they did not eliminate the nests of cancer cells that had invaded. There was some destruction of cancer cell islets and the formation of a band-like infiltration at the invasive margin by score 2 inflammatory cells. Whenever the destruction of cancer cell nests was frequent and always present, and when the inflammatory response was highly obvious (creating a cup-like zone at the invasive edge), a score of 3 was used[17]. We split the participants into two groups: one with low levels of stromal TILs (level 1) and another with high levels of stromal TILs (levels 2) and 3 (levels 3). The department's database also included additional information such as age, sex, tumour site, lymphovascular invasion (LVI), T stage, N status, histological tumour type, and stage. In order to analyse the parameters, SPSS 20 was used. A variety of criteria were used to establish a correlation.

Two seasoned pathologists, who were not privy to any patient information, performed standard pathologic investigation on each case.

Although tumour infiltrating lymphocytes (TILs) were found in the stroma (peritumoral), the emphasis of this investigation was on the TILs located near the invasive tumour margins. The invasive margin was described as the point where the tumor's invading edge met the host stroma[3].

On H&E stained tumour sections, little blue mononuclear cells were seen, which were lymphocytes, the most abundant population in the tumour stroma near the invading edge. The lymphocyte response was estimated by focussing on regions with the deepest tumour invasion[3].

Results

The research covered the period from January 2022 to August 2024 and comprised 30 instances of colorectal carcinomas identified from resection tissues collected by the Department of Pathology. A total of 16 girls and 14 men (a ratio of 0.875:1) participated in the research. There was a wide age range, from 35 to 74 years old, with 54 being the average. The colon had more tumours than the rectum. The score for TILs was determined.

The colorectal carcinomas that were examined histologically belonged to the adenocarcinoma NOS subtype. Out of the 30 cases, 16 (16%) were found to be moderately differentiated, while 4 (13%) were poorly differentiated and 0 (0% were well

DOI: 10.69605/ijlbpr_14.2.2025.58

differentiated). A total of eight instances, or 26% of the total, had lymphovascular invasion. A total of 66.6% of the lymph nodes were found to be uninvolved, whereas 33.3% revealed lymph node metastases. With 12 cases, Stage II tumours were the most prevalent, followed by 10 cases in Stage III, and 8 cases in Stage I. Our investigation did not find any instances of Stage IV.

A number of histopathologic factors, including lymphovascular invasion, lymph node involvement, grade of differentiation, and pathological staging, were shown to be significantly associated with TIL score in the research.

A negative correlation between the density of TILs at the tumor's invasive front and grade of differentiation (p=0.681), lymphovascular invasion (p=0.671), nodal involvement (p=0.081), and pathological staging (p=0.039) was found in the statistical test.

Low grade inflammation was more often linked with lymphovascular invasion than high grade inflammation.

"Table 1: Correlations between tumor-infiltrating lymphocytes and clinicopathological parameters

		Density of tumor infiltrating lymphocytes		
Variables		**Low (n=16)**	**High(n=14)**	**P value**
Age	<50 years	04	08	0.114
	>50years	12	06	
Gender	Male	10	04	0.093
	Female	06	10	
Site	Colon	06	10	0.046
	Rectum	12	02	
Histological differentiation	Adenocarcinoma Well differentiated	-	-	0.681
	Moderately differentiated	14	12	
	Poorly differentiated	02	02	
Lymphovascular invasion	Present	04	04	0.671
	Absent	08	14	

Table 2: Correlations between tumor-infiltrating lymphocytes and clinicopathological parameters

		Density of tumor infiltrating lymphocytes		
Variables		**Low**	**High**	**P value**
Tumor extension	T_1	-	-	0.374
	T_2	12	02	
	T_3	02	06	
	T_4	04	04	
Node involvement	N_0	12	08	0.081
	N_1	02	04	
	N_2	02	02	
Pathological staging	Stage I	08	-	0.039
	Stage II	04	08	
	Stage III	04	06	
	Stage IV"	-	-	

In contrast to rectal carcinomas, those in the colon showed high-grade TIL. However, there was no statistical significance (P). See table 1 and 2 for the TIL association with other metrics.

DOI: 10.69605/ijlbpr_14.2.2025.58



Category 1 Male Category 2 Female



H &E stain slide at 10X magnification Score Showing: 0 TIL



H &E stain slide at 10X magnification Score Showing: 1 TIL



H &E stain slide at 10X magnification Score Showing: 02 TIL

DOI: 10.69605/ijlbpr_14.2.2025.58



H &E stain slide at 10X magnification Score Showing: 03 T

Discussion

One of the most prevalent types of cancer in the globe are rectum and colon carcinomas. Among males, colorectal cancer ranks third, but among women, it is second (9.2%)[17].The colon was the most common site of carcinomas (16 instances). Similarly, Andreoni et al. discovered that, instead of the rectum, carcinomas tended to be colonised[18]. Every colorectal cancer in this investigation was an adenocarcinoma, according to histology. Consistent with a research by Stewart et al., we discovered that moderately differentiated adenocarcinoma was the most prevalent histological grade.

Galon et al.[19,20] hypothesised that the adaptive immune response helps to inhibit the recurrence and spread of human colorectal tumours once they are clinically identifiable. It is possible that intratumoral T cells may alter tumour stroma or tumour cells in a manner that reduces tumour cell metastatic potential[20,21].Nevertheless, it remains debatable whether tumour infiltrating lymphocytes indicate a preventive host response against cancer or an inflammatory response that promotes tumour growth[22].

As found in several other studies[23,20,24-29],According to this research, patients had a better chance of survival if their tumours included a significant amount of lymphocytic infiltration.One possible indicator of colorectal cancer is lymphocytic infiltration, which is described in the literature as a significant immune defence against tumour cells in solid tumours.

There was an increase in the T and N status in tumours with low TIL, as seen in this research.

Research in every region of the tumour microenvironment has shown that local inflammatory response is a useful clinical indication of prognosis. Numerous studies using immunohistochemistry to subtype lymphocytes have shown that higher densities of certain T-lymphocyte subpopulations are associated with better survival rates in colorectal cancer (CRC), lending credence to the idea that T-cell-mediated immunity plays a significant role in slowing the growth of CRC tumours[30,31]

Conclusions

Poor prognosis is associated with high-stage tumours when low-grade TIL is present. Therefore, in order to stratify patients based on risk, pathology reports must include TIL.

References

1. ShovanaKarki, SanjibPariyar.Tumor-infiltrating lymphocytes in colorectal carcinoma. Journal of Pathology of Nepal (2021) Vol. 11, 1859 – 1863
2. Ziyi Bai, Yao Zhou, Zifan Ye et alTumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on.Front. Immunol., 13 January 2022,Sec. Cancer Immunity and Immunotherapy;Volume 12 - 2021
3. Betsy Jose, Marjorie Correa and Jyothi S Prabhu. Association of tumour infiltrating lymphocytes with clinicopathological prognostic variables in colorectal carcinoma: A study from South India. International Journal of Clinical and Diagnostic Pathology 2020; 3(2): 49-53.
4. Mcardle CS, Hole DJ. Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mix and deprivation. Br J Cancer 2002;86:331-5.
5. Arora SP, Mahalingam D. Immunotherapy in colorectal cancer: for the select few or all. J GastrointestOncol. 2018;9:170-9.
6. Kalyan A, Kircher S, Shah H, et al. Updates on immunotherapy for colorectal cancer. J GastrointestOncol. 2018;9:160-9.
7. Vanessa Deschoolmeester1,MarcBaay 1,Eric Van Marck2.Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients.BMC Immunol.2010 Apr 12;11:19.doi:10.1186/1471-2172-11-19.
8. Titu LV, Monson JR, Greenman J. The role of CD8(+) T cells in immune responses to colorectal cancer. Cancer ImmunolImmunother. 2002;51:235–247. doi: 10.1007/s00262-002-0276-4.
9. Loose D, Wiele C Van de. The immune system and cancer. Cancer BiotherRadiopharm. 2009;24:369–376. doi: 10.1089/cbr.2008.0593.
10. Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer. 2006;118:6–10. doi: 10.1002/ijc.21303.
11. Atkinson EA, Bleackley RC. Mechanisms of lysis by cytotoxic T cells. Crit Rev Immunol. 1995;15:359–384. doi: 10.1615/critrevimmunol.v15.i3-4.90.
12. Koch M, Beckhove P, Op den Winkel J, Autenrieth D, Wagner P, Nummer D. Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective

DOI: 10.69605/ijlbpr_14.2.2025.58

activation and cytotoxic activity in situ. Ann Surg. 2006;244:986–992. doi: 10.1097/01.sla.0000247058.43243.7b.
13. Parmiani G. Tumor-infiltrating T cells--friend or foe of neoplastic cells? N Engl J Med. 2005;353:2640–1. doi: 10.1056/NEJMp058236.
14. Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H. Inflammation and prognosis in colorectal cancer. Eur J Cancer. 2005;41:2645 2654.doi:10.1016/j.ejca.2005.07.017.
15. Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol. 1999;154:1805–13. doi: 10.1016/S0002-9440(10)65436-3.
16. Prall F, Duhrkop T, Weirich V, Ostwald C, Lenz P, Nizze H. Prognostic role of CD8+tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Human Path. 2004;35:808–816. doi: 10.1016/j.humpath.2004.01.022.
17. Shah S, Shrestha S, Shah JN et al. Clinico-pathological characteristics of colorectal carcinoma atuniversity teaching hospital, Nepal. Journal of Patan Academy of Health Sciences. 2014;1:35-8.
18. Stewart B., Wild C.P., editors. World Cancer Report 2014. International Agency for Research on Cancer (IARC); Lyon, France: 2014.
19. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964. doi: 10.1126/science.1129139.
20. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007;67:1883–1886. doi: 10.1158/0008-5472.CAN-06-4806.
21. Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A, Berger A. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 2009;69:2685–2693. doi: 10.1158/0008-5472.CAN-08-2654.
22. Chiba T, Ohtani H, Mizoi T, Naito Y, Sato E, Nagura H. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer.2004;91:1711–1717. doi: 10.1038/sj.bjc.6602201.
23. Koch M, Beckhove P, Op den Winkel J, Autenrieth D, Wagner P, Nummer D. Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann Surg. 2006;244:986–992. doi: 10.1097/01.sla.0000247058.43243.7b.
24. Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G. Immunology and immunotherapy of colorectal cancer. Crit Rev OncolHematol. 2003;46:33–57. doi: 10.1016/S1040-8428(02)00159-2.
25. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet. 1987;1:1303–1306. doi: 10.1016/S0140-6736(87)90552-6.
26. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol. 1997;182:318–324. doi: 10.1002/(SICI)1096-9896(199707)182:3<318::AID-PATH862>3.0.CO;2-6.
27. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol. 1999;189:487–495. doi: 10.1002/(SICI)1096-9896(199912)189:4<487::A-ID-PATH484>3.0.CO;2-I.
28. Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep. 2003;10:309–313.
29. Pages F, Berger A, Camus M, Sanchez Cabo F, Costes A, Molidor R. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66. doi: 10.1056/NEJMoa051424.
30. Halama N, Michel S, Kloor M, Zoernig I, Pommerencke T, von Knebel DM. The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun. 2009;9:1.
31. Richards CH, Roxburgh CS, Powell AG, Foulis AK, Horgan PG, McMillan DC. The clinical utility of the local inflammatory response in colorectal cancer. European journal of cancer. 2014; 50(2):309-19. 15.
32. Huang CY, Chiang SF, Ke TW, Chen TW, You YS, Chen WT et al. Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II–III colorectal cancer. Scientific reports. 2018; 8(1):1-0.